US 12,251,470 B2
Lipid nanoparticle formulations
James Heyes, Vancouver (CA); Adam Judge, Bainbridge Island, WA (US); Kieu Mong Lam, Richmond (CA); Lorne Ralph Palmer, Vancouver (CA); and Petra Schreiner, Burnaby (CA)
Assigned to ARBUTUS BIOPHARMA CORPORATION, Burnaby (CA)
Appl. No. 17/291,942
Filed by ARBUTUS BIOPHARMA CORPORATION, Burnaby (CA)
PCT Filed Nov. 8, 2019, PCT No. PCT/US2019/060582
§ 371(c)(1), (2) Date May 6, 2021,
PCT Pub. No. WO2020/097540, PCT Pub. Date May 14, 2020.
Claims priority of provisional application 62/758,088, filed on Nov. 9, 2018.
Prior Publication US 2022/0000778 A1, Jan. 6, 2022
Int. Cl. A61K 9/1272 (2025.01); A61K 9/51 (2006.01); A61K 31/713 (2006.01); B82Y 5/00 (2011.01); C12N 15/113 (2010.01)
CPC A61K 9/1272 (2013.01) [A61K 9/5123 (2013.01); A61K 31/713 (2013.01); C12N 15/113 (2013.01); B82Y 5/00 (2013.01); C12N 2310/14 (2013.01); C12N 2320/30 (2013.01)] 10 Claims
 
1. A lipid nanoparticle comprising:
(a) one or more nucleic acid molecules, wherein the nucleic acid molecules are mRNA molecules;
(b) cholesterol;
(c) DSPC;
(d) PEG-C-DMA; and
(e) a cationic lipid of formula:

OG Complex Work Unit Chemistry
or a salt thereof, wherein the molar percentage of total lipid for PEG-C-DMA, cationic lipid, cholesterol, and DSPC are as follows:
PEG-C-DMA: 1.485-1.515;
cationic lipid: 49.5-50.5;
cholesterol: 38.115-38.885; and
DSPC: 9.9-10.1.